Table 1 Summary of research aims and analysis plan sources

Aim 1

Convenient access to care

Aim 1a.

Ease of access

New users of HC

Clinical cohort

APAC cohort

Initiation of HC will be measured as a prescription for HC with no history of prior HC utilization in the preceding 30 days.

Aim 1a.

Ease of access

Number of months of contraceptive dispensed

Clinical cohort

APAC cohort

Number of months and type of contraceptive coverage a woman receives per health system interaction.

Aim 1b.

Out of pocket payments

Amount a woman needs to pay per month of coverage

Clinical cohort

Amount a woman reports paying for care.

Aim 2

Safety

Aim 2a. Appropriate and safe prescription of HC for all women

Women with common contraindications to estrogen who are using a progestin only method

Clinical cohort

APAC cohort

Contraindications will be identified as having received an ICD-9 or ICD-10 diagnosis code for hypertension, diabetes, migraines with aura, epilepsy, or blood clots in the last year on a claim in the last year. Pharmacy claims for these conditions will be identified with NDC codes.

Aim 2b.

Access to follow-up

Ability to access follow-up care

Clinical cohort

Utilization and location of follow-up after HC initiation.

Aim 3

Comparative Effectiveness

Aim 3a. Contraceptive continuation

Ongoing use of a contraceptive method

Clinical cohort

APAC cohort

Ongoing use of contraceptive method (self-reported).

No breaks in contraceptive claims of greater than 30 days.

Missed days of contraception (self-reported).

Gap of 3–29 days between the conclusion of one HC prescription and the fill of the next.

Aim 3b.

Pregnancy incidence

Pregnancies experienced by contracepting women

Clinical cohort

APAC cohort

Self-reported pregnancy.

Medical claims for any episode of pregnancy related care in study cohort using ICD9 &10 codes.